What is FLT3-ITD+ AML? | VANFLYTA® (quizartinib)

Why knowing if you have FLT3-ITD+ AML matters

Microscope icon

Once you are diagnosed with acute myeloid leukemia (AML), doctors perform lab tests to look for genetic changes, such as the FLT3-ITD mutation. This mutation may show up when you are diagnosed, or later on.

Gene mutation icon

If testing shows that you have FLT3-ITD+ AML, it means your leukemia cells carry this mutation. Knowing this information is important because it can help your doctor determine which treatment options may work best for you.

Quick Poll

Do you know the difference between FLT3-ITD and FLT3-TKD mutations?

Person with checkmark icon

Person speaking icon

Person who doesn’t know icon

Person with checkmark icon

Person speaking icon

I know some 50%

Person who doesn’t know icon

I don't know 50%

See how others responded

FLT3-ITD+ AML

Knowing which mutation you may have can help your doctor select the appropriate treatment for you. Doctors test for mutations with bone marrow or blood tests. This gives them more information about your type of AML.

In AML, there are many mutations, but one of the most common is the FLT3 mutation. FLT3 mutations include the ITD subtype, which can be present at diagnosis or appear later on.

The ITD mutation is the most common type of mutation in the FLT3 gene and is known to cause cancer to grow or spread quickly. Because of this, getting tested for FLT3 mutations, specifically the ITD mutation, is key to getting you on the appropriate treatment.

Portrayal of a doctor testing for the FLT3-ITD mutation

TESTING FOR THE FLT3-ITD MUTATION IS AN IMPORTANT STEP IN CREATING A TREATMENT PLAN THAT IS PERSONALIZED TO YOUR TYPE OF AML.

Actor potrayal.

TESTING FOR THE FLT3-ITD MUTATION IS AN IMPORTANT STEP IN CREATING A TREATMENT PLAN THAT IS PERSONALIZED TO YOUR TYPE OF AML.

If the blood and bone marrow test found that you have the FLT3-ITD mutation, doctors may prescribe a FLT3 inhibitor that specifically targets the FLT3-ITD mutation.

Treatment for FLT3-ITD+ AML

When you or a loved one is first diagnosed with FLT3-ITD+ AML, it can be overwhelming. Stay in regular contact with your doctor and ask any questions to help you better understand the next steps of treatment.

To help, we have created a discussion guide that lists a series of questions to support conversations with you or your loved one's prescribing physician. We hope this guide is helpful and gives you confidence during your VANFLYTA treatment journey.

Discussion guide icon

Download the
Discussion Guide

Next: About VANFLYTA

Important Safety Information

What is the most important information I should know about VANFLYTA^® (quizartinib)?

VANFLYTA may cause serious side effects, including changes in the electrical activity of your heart (QT prolongation), torsades de pointes, and your heart stopping (cardiac arrest). QT prolongation can cause irregular heartbeats that can be life-threatening or lead to death.

Your healthcare provider will check your heart’s electrical activity with an electrocardiogram (ECG) and will do blood tests to check your potassium and magnesium levels before and during treatment.
Call your healthcare provider right away if you have any of the following: irregular heartbeat, dizziness, lightheadedness, fainting (even briefly), chest pain, diarrhea, or vomiting. You may need hospital care. Always carry the VANFLYTA Patient Wallet Card provided by your healthcare provider.
Because of the risk of QT prolongation, torsades de pointes, and cardiac arrest, VANFLYTA is available only through a restricted program called the VANFLYTA Risk Evaluation and Mitigation Strategy (REMS).

Do not take VANFLYTA if you have very low potassium, very low magnesium, long QT syndrome, or a history of ventricular arrhythmias or torsades de pointes.

Before taking VANFLYTA, tell your healthcare provider about all of your medical conditions, including if you: have any heart problems, have low blood levels of potassium or magnesium, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. VANFLYTA may harm your baby. Do not breastfeed during treatment with VANFLYTA and for 1 month after the last dose.

If you are female and able to become pregnant, your healthcare provider will do a pregnancy test within 7 days before starting treatment. You should use effective birth control (contraception) during treatment and for 7 months after your last dose. Tell your healthcare provider right away if you become pregnant or think you may be pregnant.
If you are male with a female partner who can become pregnant, use effective birth control during treatment and for 4 months after your last dose.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. VANFLYTA may interact with other medicines, which can cause side effects. Especially tell your healthcare provider if you take St. John’s wort. Do not take St. John’s wort during treatment with VANFLYTA.

What are the most common side effects of VANFLYTA?

The most common side effects of VANFLYTA include: low white blood cell counts, changes in levels of electrolytes in the blood, changes in liver function tests, low white blood cell counts with fever, diarrhea, mouth sores, nausea, stomach (abdominal) pain, serious infection throughout the body and organs (sepsis), headache, vomiting, upper respiratory tract infections, low platelet counts, decreased appetite, fungal infections, nosebleed, herpes virus infections, trouble sleeping, abnormal electrocardiogram (QT prolongation), upset stomach, low red blood cell counts (anemia), and eye irritation.

Your healthcare provider will do blood tests and ECGs before you start and during treatment. If you develop certain side effects while taking VANFLYTA, your healthcare provider may decrease your dose, pause treatment, or stop treatment permanently.

VANFLYTA may affect fertility in both females and males, which may affect your ability to have children. Talk to your healthcare provider if you have concerns about your fertility.

These are not all the possible side effects of VANFLYTA. Call your doctor for medical advice about side effects. You are encouraged to report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

What is VANFLYTA?

VANFLYTA is a prescription medicine used with certain chemotherapy medicines and alone as maintenance therapy to treat adults with newly diagnosed acute myeloid leukemia (AML) that has a FLT3-ITD mutation. Your healthcare provider will test for this mutation to determine if VANFLYTA is right for you. VANFLYTA is not for use alone as maintenance therapy after a hematopoietic stem cell transplant. It is not known if VANFLYTA is safe and effective in children.

Please see Full Prescribing Information, including Boxed WARNINGS, and Medication Guide.

Back to Top